MarketFriction

Abbott India Ltd

NSE ABBOTINDIA · BSE 500488 · Pharmaceuticals
₹26,840.00 -1.05%
NSE close2026-10-01
52 week range25,135.00 - 30,655.00
Market cap₹57,949 Cr.
P/E35.9
Nifty 500Midcap 150Nifty PharmaNifty Healthcare IndexNifty MNC Price band 20% Delivery 55.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,4941,4371,4391,5581,6331,6141,6051,7381,7571,7241,7101,814
Expenses1,1131,0491,1091,1671,1941,1781,1761,2931,2551,2611,2291,291
Operating Profit381388330391439436429446502463481522
OPM %25%27%23%25%27%27%27%26%29%27%28%29%
Other Income565681676072767370707675
Interest333322468566
Depreciation181818181818181919191920
Profit before tax415422390437479488483493546509531572
Tax %25%26%26%25%25%26%24%26%24%26%26%25%
Net Profit313311287328359361367366415376395429
EPS in Rs147.27146.35135.09154.36168.76169.78172.73172.18195.43176.93185.86201.66
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,6142,9033,2983,6794,0934,3104,9195,3495,8496,4096,9297,004
Expenses2,2502,5052,7743,0743,3363,3883,8324,1434,3964,7145,0375,035
Operating Profit3653985256057579221,0881,2061,4531,6951,8921,969
OPM %14%14%16%16%18%21%22%23%25%26%27%28%
Other Income50571171131148177154248275288291
Interest3242918191612112525
Depreciation141616176058667071727676
Profit before tax3984366216998039261,0801,2741,6181,8872,0792,158
Tax %36%37%35%36%26%25%26%25%26%25%25%
Net Profit2552774014505936917999491,2011,4141,5521,615
EPS in Rs120.12130.19188.82211.93279.04325.04375.87446.80565.30665.64730.39759.88
Dividend Payout %29%31%29%31%90%85%73%73%73%71%90%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth10%10%9%6%
Compounded Profit Growth20%17%18%11%
Stock Price CAGR19%4%6%-7%
Return on Equity31%34%35%34%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital212121212121212121212121
Reserves9161,1741,3661,6721,9872,4102,5812,7993,1673,6784,2124,753
Borrowings0000017515315211383197172
Other Liabilities4364216797239329401,0861,2531,2541,4111,4871,556
Total Liabilities1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502
Fixed Assets9610811081105270251271237225336331
CWIP43621211410186
Investments000000000000
Other Assets1,2741,5051,9502,3332,8353,2753,5893,9524,3154,9585,5636,165
Total Assets1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity2152493071534996267279488931,2131,0121,319
Cash from Investing Activity-187-77-155-215-257-401-72-396-148-416182-371
Cash from Financing Activity-58-80-90-102-143-217-582-637-639-745-925-1,066
Net Cash Flow-309162-16599873-8610752269-118
Free Cash Flow1992262871805046117049048601,1659601,307
CFO/OP106%109%117%68%125%113%104%114%102%111%86%98%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days212022292728212122202219
Inventory Days10791107112106831109480709294
Days Payable545610192116104116122109114110109
Cash Conversion Cycle7454284917814-6-8-2433
Working Capital Days3032216322104-7-8-14992
ROCE %40%38%34%41%37%35%35%38%41%46%46%45%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%
FIIs0.19%0.18%0.18%0.18%0.17%0.17%0.16%0.16%0.16%0.19%0.27%0.38%
DIIs8.83%8.73%8.91%8.81%9.00%9.01%8.91%9.18%9.11%9.00%8.93%8.77%
Public16.01%16.09%15.92%16.01%15.86%15.85%15.94%15.67%15.74%15.83%15.81%15.85%
No. of Shareholders68,88572,25269,38271,58869,44967,89269,93467,58471,19975,80175,86678,320

Fundamentals

Market Cap₹ 57,949 Cr.
Current Price₹ 27,270
Stock P/E35.9
Book Value₹ 2,247
ROCE44.8 %
ROE34.4 %
Dividend Yield1.93 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)6%
Compounded Profit Growth (TTM)11%
Standalone figures.
Valuation
Market capRs 57,033 Cr
Enterprise valueRs 54,950 Cr
P/E (TTM)35.32x
Price to book11.95x
Price to sales8.14x
EV / EBITDA24.32x
EV / EBIT25.17x
EV / sales7.85x
Price to cash flow43.23x
Earnings yield2.83%
Dividend yield2.44%
P/E, 3-year average43.20x
P/B, 3-year average14.18x
P/E, 5-year average45.22x
P/B, 5-year average14.12x
Profitability
Operating margin (excl. other income)27.31%
Operating margin (incl. other income)31.46%
EBITDA margin32.26%
Pre-tax margin30.81%
Net profit margin23.05%
Net margin, latest quarter23.63%
ROE34.46%
ROCE44.89%
ROA24.99%
ROE, 3-year average35.00%
ROCE, 3-year average45.72%
ROA, 3-year average25.03%
ROE, 5-year average33.21%
ROCE, 5-year average43.33%
ROA, 5-year average23.31%
ROIC (approx.)60.56%
Tax rate25.36%
Other income / net worth6.04%
Growth
Sales growth (latest year)8.11%
Profit growth (latest year)9.73%
Sales CAGR, 3 years9.01%
Sales CAGR, 5 years9.96%
Profit CAGR, 3 years17.80%
Profit CAGR, 5 years17.58%
Sales growth QoQ6.09%
Profit growth QoQ8.51%
Sales growth YoY (latest quarter)4.33%
Profit growth YoY (latest quarter)17.13%
Per share
EPS (TTM)Rs 759.87
EPS (latest year)Rs 730.39
EPS (latest quarter)Rs 201.66
EPS, 3-year averageRs 653.78
EPS, 5-year averageRs 556.80
Book value per shareRs 2,246.75
Sales per shareRs 3,296.29
Cash flow per shareRs 620.84
Free cash flow per shareRs 615.08
Dividend per share (latest year)Rs 656.02
Dividend per share, 3-year averageRs 513.68
Dividend per share, 5-year averageRs 428.21
Dividends
Dividend payout89.82%
Dividend payout, 3-year average77.90%
Dividend payout, 5-year average75.92%
Efficiency
Asset turnover1.07x
Fixed asset turnover20.91x
Inventory turnover4.07x
Inventory days90 days
Debtor days19 days
Debtors turnover19.16x
Creditor days109 days
Cash conversion cycle3 days
Working capital days2 days
Leverage
Total debtRs 172 Cr
Cash and bankRs 2,255 Cr
Net debtRs -2,083 Cr
Debt to equity0.04x
Net debt / EBITDA-0.92x
Interest coverage87.06x
Owners' fund to total sources73.43%
Debt to assets2.65%
Cash flow
Cash from Operating Activity (latest year)Rs 1,319 Cr
Cash from Investing Activity (latest year)Rs -371 Cr
Cash from Financing Activity (latest year)Rs -1,066 Cr
Net Cash Flow (latest year)Rs -118 Cr
Free cash flow (latest year)Rs 1,307 Cr
FCFE (approx.: FCF + change in debt)Rs 1,282 Cr
Cash from ops / profit, 5 years0.91x
Sales to cash flow5.25x
Statement figures
Net sales (TTM)Rs 7,004 Cr
Net sales (latest year)Rs 6,929 Cr
Sales (latest quarter)Rs 1,814 Cr
Operating profit excl. other income (latest year)Rs 1,892 Cr
Operating profit (latest quarter)Rs 522 Cr
Other income (TTM)Rs 291 Cr
EBITDA (TTM)Rs 2,260 Cr
PBDT (TTM)Rs 2,235 Cr
Profit before tax (TTM)Rs 2,158 Cr
Tax (latest year)Rs 527 Cr
Net profit (TTM)Rs 1,615 Cr
Net profit (latest year)Rs 1,552 Cr
Net profit (latest quarter)Rs 429 Cr
Depreciation (TTM)Rs 76 Cr
Depreciation (latest quarter)Rs 20 Cr
Interest (TTM)Rs 25 Cr
Cost of goods sold (latest year)Rs 3,852 Cr
Total expenditure (latest year)Rs 5,037 Cr
Total income (latest year)Rs 7,217 Cr
Share capitalRs 21 Cr
ReservesRs 4,753 Cr
Shareholders' fundsRs 4,774 Cr
Total assetsRs 6,502 Cr
Net blockRs 331 Cr
Capital work in progressRs 6 Cr
ReceivablesRs 362 Cr
InventoryRs 947 Cr
Other liabilitiesRs 1,556 Cr
Shares outstanding (crore)2.12
Ownership
Promoter holding74.99% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 35.3 is at the 6th percentile of its own 9.4-year range (median 51.1, low 32.0, high 83.7).
P/B 11.95 is at the 27th percentile (median 14.14).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodABBOTINDIANifty 50Difference
1 week-0.1%-2.8% +2.7 pts
1 month+2.7%-6.8% +9.5 pts
3 months+3.6%-7.6% +11.3 pts
6 months+3.6%+0.4% +3.2 pts
1 year-11.1%-9.9% -1.2 pts
2 years-5.3%-13.6% +8.3 pts
3 years+15.8%+14.2% +1.6 pts
5 years+21.8%+27.9% -6.1 pts
144 mutual fund schemes hold about ₹4,073 Cr. Over three months 30 bought more and 73 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
SBI Large & Midcap Fund1.88%796 -5%
Nippon India Multi Cap Fund0.67%379 +10%
Axis Midcap Fund1.00%343 -22%
Canara Rob Large and Mid Cap Fund1.30%342 -10%
Nippon India Pharma Fund2.13%202 -2%
ICICI Pru Healthcare Fund-2.38%166 -7%
Tata Mid Cap Fund2.07%129 +13%
Tata Large & Mid Cap Fund1.35%103 +27%
PGIM India Midcap Fund0.76%85 -4%
Tata India Pharma & Healthcare Fund5.44%84 +5%
Canara Rob Flexi Cap Fund0.56%76 -13%
Aditya Birla SL Balanced Advantage Fund0.69%70 +100%
Nippon India Vision Large & Mid Cap Fund0.87%69 +100%
Canara Rob Large Cap Fund0.36%62 -14%
WOC Mid Cap Fund0.72%54 -19%
Tata Flexi Cap Fund1.46%54 +9%
Canara Rob Mid Cap Fund0.89%46 -9%
Edelweiss Balanced Advantage Fund(Q0.34%46 -5%
Bandhan Large & Mid Cap Fund0.22%46 +100%
Bank of India Aggressive Hybrid Fund1.89%39 -19%
Baroda BNP Paribas Mid Cap Fund1.41%37 -4%
Tata ELSS-Tax Saver Fund0.77%37 -5%
Tata Business Cycle Fund1.39%36 +100%
Bank of India Mid Cap Fund4.38%34 -7%
LIC MF Multi Cap Fund1.45%33 -2%

Red flags

F-score 5 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹1,814 Cr +4.4% vs Jun 2025. Net profit ₹429 Cr +17.2%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share
2025-07-25Dividend - Rs 475 Per Share
2024-07-19Dividend - Rs 410 Per Share
2023-07-21Dividend - Rs 180 Per Share/ Special Dividend Rs 145 Per Share
2022-08-02Annual General Meeting/Dividend - Rs 145 Per Share/Special Dividend- 130 Per Share
2021-07-19 Annual General Meeting/Dividend - Rs 120 Per Share Special Dividend 155 Per Share
2020-08-28 Annual General Meeting/Dividend - Rs 107 Per Share And Special Dividend - Rs 143 Per Share
2019-08-13 Annual General Meeting/ Final Dividend - Rs 50 Per Share/ Special Dividend - Rs 15 Per Share
2018-07-10 Annual General Meeting / Final Dividend- Rs 50 Per Share / Special Dividend- Rs 5 Per Share
2017-07-10 Annual General Meeting/Dividend Rs 40/- Per Share
2016-07-08 Annual General Meeting/Divided - Rs 35/- Per Share
2015-07-22Annual General Meeting/Dividend - Rs 31/- Per Share
2014-07-23Annual General Meeting / Final Dividend - Rs 23/- Per Share
2013-04-16Annual General Meeting And Dividend Rs.17 Per Share
2012-05-04Annual General Meeting And Dividend Rs.17/- Per Share
2011-04-19Annual General Meeting / Final Dividend - Rs.17/- Per Share
2010-03-03Agm/Div-Rs.17/- Per Share
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Abbott India Ltd?

Abbott India Ltd (ABBOTINDIA) has a market capitalisation of Rs 57,949 Cr. at the 2026-10-01 close.

What is the P/E ratio of Abbott India Ltd?

Abbott India Ltd trades at a P/E of 35.9 on trailing twelve-month profit, at the 2026-10-01 close.

What were Abbott India Ltd's latest quarterly results?

In the Jun 2026 quarter, Abbott India Ltd sales was Rs 1,814 Cr (+4.4% vs Jun 2025) and net profit was Rs 429 Cr.

What is the 52-week high and low of Abbott India Ltd?

The 52-week high is Rs 30,655.00 and the 52-week low is Rs 25,135.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03